June 28, 2025 –The Chinese Biopharmaceutical Association (CBA-China) Annual Conference concluded successfully in Suzhou, gathering over 1200 leaders from political, industrial, academic, and research sectors to explore technological advancements and global collaboration.
Medicilon at CBA-China 2025: Showcasing Innovation & Global Leadership
As a leading full-service preclinical R&D CRO, Medicilon actively participated in the CBA-China 2025 Annual Conference, leveraging the platform to share its cutting-edge technical expertise, pioneering innovations, and global collaboration frameworks.
Medicilon Booth# CT08
Its booth, CT08, attracted significant attention, with the Medicilon team showcasing its technical strengths in preclinical R&D, its one-stop service platform (encompassing peptides, ADCs, nucleic acid drugs, and other new modalities), and its cutting-edge innovations. Attendees praised Medicilon’s capabilities and achievements.
Peptide Forum
A focal point was the Peptide Forum, where Dr. Yongmei Xu, Head of Medicilon Peptide Platform, delivered opening remarks. The forum highlighted the growing importance of peptides in drug development due to their unique advantages, including high biological activity, strong specificity, and reduced drug resistance. Discussions centered on protein peptide drug production and R&D trends, emerging PDCs, GLP-1 agonists, and the role of AI in peptide R&D.
Medicilon emphasized its internationally leading peptide drug design platform and comprehensive service offerings, aiming to accelerate the development of new peptide drug candidates and foster collaboration within the industry. Medicilon’s commitment is to partner with industry stakeholders to advance peptide drug development.
Dr. Yongmei Xu, Head of Medicilon Peptide Platform
Harvard & MIT Alumni Association
“Harvard & MIT Alumni Association” explored using multi-omics, target discovery, and engineered drug design to combat tumor immunotherapy resistance, informing next-generation therapies. Global alumni collaborated to promote cross-border biomedical innovation by merging scientific exploration with industrial practice, offering insights and strategies for global health challenges.
The panel discussed: the industrialization and global strategy of medical technology through industry-university-research-medical-investment collaboration; AI and biomedicine integration, emphasizing AI’s role in drug discovery, clinical trials, and digital health, while addressing ethical implications; and advancements in innovative drug R&D and translational medicine, highlighting breakthroughs in cell therapy, gene editing, and regenerative medicine, and their clinical translation challenges.
